Secondary neoplasms in patients treated for cancer: Etiology and perspective

C. N. Coleman

Research output: Contribution to journalArticle

Abstract

The exact risk of secondary neoplasms in patients treated for cancer is difficult to ascertain due to a nonspecific increased risk, a possible genetic or congenital predisposition, and tumor multicentricity. Second tumors now considered 'treatment-related' may in fact, be 'syndrome-related', as in the case with secondary osteosarcoma in patients with retinoblastoma. A wide variety of second tumors have been described with solid tumors having latency periods of 10 years and with leukemia 5 years. Recently secondary lymphomas have been reported in Hodgkin's disease patients which may be related to their altered immunity. The 10-year risk of developing second cancers in patients with Hodgkin's disease or pediatric malignancies is approximately 10%, but the risk for all newly diagnosed cancer patients is below 1%. Aggressive treatment has improved curability; however, prolonged administration of chemotherapy, especially alkylating agents, and the use of radiotherapy plus chemotherapy have been major risk factors in the current excess of second cancers. Carcinogenic treatment should be avoided; however, patient curability must not be compromised until less toxic treatments are proven to be equally effective.

Original languageEnglish (US)
Pages (from-to)188-200
Number of pages13
JournalRadiation Research
Volume92
Issue number1
StatePublished - 1982
Externally publishedYes

Fingerprint

etiology
neoplasms
cancer
tumors
Neoplasms
chemotherapy
Hodgkin disease
Second Primary Neoplasms
Hodgkin Disease
drug therapy
leukemias
immunity
Drug Therapy
Retinoblastoma
Poisons
radiation therapy
Alkylating Agents
Osteosarcoma
osteosarcoma
Therapeutics

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biophysics
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Secondary neoplasms in patients treated for cancer : Etiology and perspective. / Coleman, C. N.

In: Radiation Research, Vol. 92, No. 1, 1982, p. 188-200.

Research output: Contribution to journalArticle

@article{73f264cefac24ab9a7b5e18d370e77f9,
title = "Secondary neoplasms in patients treated for cancer: Etiology and perspective",
abstract = "The exact risk of secondary neoplasms in patients treated for cancer is difficult to ascertain due to a nonspecific increased risk, a possible genetic or congenital predisposition, and tumor multicentricity. Second tumors now considered 'treatment-related' may in fact, be 'syndrome-related', as in the case with secondary osteosarcoma in patients with retinoblastoma. A wide variety of second tumors have been described with solid tumors having latency periods of 10 years and with leukemia 5 years. Recently secondary lymphomas have been reported in Hodgkin's disease patients which may be related to their altered immunity. The 10-year risk of developing second cancers in patients with Hodgkin's disease or pediatric malignancies is approximately 10{\%}, but the risk for all newly diagnosed cancer patients is below 1{\%}. Aggressive treatment has improved curability; however, prolonged administration of chemotherapy, especially alkylating agents, and the use of radiotherapy plus chemotherapy have been major risk factors in the current excess of second cancers. Carcinogenic treatment should be avoided; however, patient curability must not be compromised until less toxic treatments are proven to be equally effective.",
author = "Coleman, {C. N.}",
year = "1982",
language = "English (US)",
volume = "92",
pages = "188--200",
journal = "Radiation Research",
issn = "0033-7587",
publisher = "Radiation Research Society",
number = "1",

}

TY - JOUR

T1 - Secondary neoplasms in patients treated for cancer

T2 - Etiology and perspective

AU - Coleman, C. N.

PY - 1982

Y1 - 1982

N2 - The exact risk of secondary neoplasms in patients treated for cancer is difficult to ascertain due to a nonspecific increased risk, a possible genetic or congenital predisposition, and tumor multicentricity. Second tumors now considered 'treatment-related' may in fact, be 'syndrome-related', as in the case with secondary osteosarcoma in patients with retinoblastoma. A wide variety of second tumors have been described with solid tumors having latency periods of 10 years and with leukemia 5 years. Recently secondary lymphomas have been reported in Hodgkin's disease patients which may be related to their altered immunity. The 10-year risk of developing second cancers in patients with Hodgkin's disease or pediatric malignancies is approximately 10%, but the risk for all newly diagnosed cancer patients is below 1%. Aggressive treatment has improved curability; however, prolonged administration of chemotherapy, especially alkylating agents, and the use of radiotherapy plus chemotherapy have been major risk factors in the current excess of second cancers. Carcinogenic treatment should be avoided; however, patient curability must not be compromised until less toxic treatments are proven to be equally effective.

AB - The exact risk of secondary neoplasms in patients treated for cancer is difficult to ascertain due to a nonspecific increased risk, a possible genetic or congenital predisposition, and tumor multicentricity. Second tumors now considered 'treatment-related' may in fact, be 'syndrome-related', as in the case with secondary osteosarcoma in patients with retinoblastoma. A wide variety of second tumors have been described with solid tumors having latency periods of 10 years and with leukemia 5 years. Recently secondary lymphomas have been reported in Hodgkin's disease patients which may be related to their altered immunity. The 10-year risk of developing second cancers in patients with Hodgkin's disease or pediatric malignancies is approximately 10%, but the risk for all newly diagnosed cancer patients is below 1%. Aggressive treatment has improved curability; however, prolonged administration of chemotherapy, especially alkylating agents, and the use of radiotherapy plus chemotherapy have been major risk factors in the current excess of second cancers. Carcinogenic treatment should be avoided; however, patient curability must not be compromised until less toxic treatments are proven to be equally effective.

UR - http://www.scopus.com/inward/record.url?scp=0019904785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019904785&partnerID=8YFLogxK

M3 - Article

C2 - 7134383

AN - SCOPUS:0019904785

VL - 92

SP - 188

EP - 200

JO - Radiation Research

JF - Radiation Research

SN - 0033-7587

IS - 1

ER -